CHAMGAP
APPROVEDReviewed and approved by the Chamgap Editorial Team (2026-07-19). The draft was written by AI, the existence of all 4 cited sources was verified at the original page, and the verdict passed blind grading and adversarial audit. Methodology v0.6.
Verdict No. 696 · Search date 2026-07-19 · Methodology v0.6

Caralluma fimbriata extract,
does it really help with Weight loss through reduced appetite and waist circumference?

30-Second Summary
D
Evidence Grade D · 35 · Safety unknown
Direct human trials and quantitative synthesis show no weight loss, with only weak waist and hunger signals
What the
research shows
The weight-loss claim for Caralluma fimbriata extract is rated D. An independent placebo-controlled trial of 89 participants found no between-group benefit for weight, BMI, waist circumference, or appetite after 12 weeks. A systematic review of seven studies and quantitative synthesis of four placebo-controlled trials estimated a weight effect of about -0.04 kg, effectively zero. A -1.59-cm waist signal and borderline hunger signal are weak secondary findings and do not rescue the overall weight-loss claim. Direct null human weight outcomes support D with 35 points.
What the
ads claim
Marketing turns appetite suppression directly into fat loss and reliable weight reduction. The evidence is limited to short-term signals for hunger and waist circumference with particular extracts and does not establish sustained weight loss or clinical outcomes.
*

Useful facts when choosing a product

  • Caralluma fimbriata is distinct from garcinia, hoodia, and cissus, and this verdict applies only to Caralluma fimbriata extract.
  • Trials commonly used 1 g/day of standardized extract for 8 to 16 weeks, but retail products can differ in extraction ratio and pregnane-glycoside standardization.
  • Some trials reported mild gastrointestinal effects such as nausea, abdominal discomfort, constipation, or diarrhea, while long-term safety data remain limited.
  • A change in appetite does not necessarily reduce energy intake or body weight, so appetite, waist circumference, and weight must be evaluated as separate outcomes.
Gap Measurement · Verdict 696 · D 35
What advertising claims
What independent, higher-quality research supports
△ GAP
01

What the research actually shows

Kuriyan et al. 2007 reported lower hunger and waist circumference with 1 g/day in 50 participants but no clear weight effect. Arora et al. 2015 tested 1 g/day for 12 weeks in 89 participants and found no placebo-adjusted effect on weight, BMI, waist, hip, waist-to-hip ratio, or appetite. Rao et al. 2021 reported weight maintenance and selected waist and intake signals among 83 completers using a supplied Slimaluma extract, without confirming clinical weight loss. The 2021 systematic review included seven studies and quantitatively synthesized four placebo-controlled trials, finding an effectively null weight effect of about -0.04 kg, with only a -1.59-cm waist signal and borderline hunger signal.

02

Why this is classified as D (35)

D. The 89-person placebo-controlled trial was null for weight, BMI, waist circumference, and appetite, and the quantitative synthesis of four placebo-controlled trials estimated a weight effect of about -0.04 kg, effectively zero. The -1.59-cm waist result and borderline hunger signal are weak and do not support the direct clinical claim of weight loss. Prioritizing null human weight outcomes yields D with 35 points; mild gastrointestinal effects and product variability remain separate safety issues.

Counterpoint. Diet quality, energy intake, physical activity, sleep, and evidence-based obesity treatment when indicated remain central; this supplement has not been shown to replace them.

Rejudgment record. Reassessment (cross-check reflected) — Prioritized the null weight, BMI, waist, and appetite findings in the 89-person placebo-controlled trial and the approximately -0.04-kg weight effect in a quantitative synthesis of four placebo-controlled trials, while recognizing only limited -1.59-cm waist and borderline hunger signals

Sub-claim grades by effect

This ingredient is marketed for several effects. A single overall grade blends strong and weak claims together, so each effect is graded separately here. The overall grade reflects the strongest disconfirming or core claim.

Effect (sub-claim)GradeBasis
Weight loss through reduced appetite and waist circumferenceDThe 89-person placebo trial and meta-analysis found null weight and BMI effects, with an effect near zero.
Weak signals for waist circumference and hungerCOnly a -1.59-cm waist result and a borderline hunger signal were limited positives.
Attribution of an appetite mechanism to weight loss?Attributing the appetite mechanism to actual weight loss is unstable.

Cross-check — Codex and Claude

This verdict was drafted by Codex through literature review and source-existence checks, cross-checked through blind grading and adversarial audit, and settled by reapplying the methodology boundary rules. Cases with split grades were resolved through rejudgment.
03

Evidence Table

StudyDesignSampleFundingEndpointResultWeight
Arora E et al. 2015Randomized single-blind placebo-controlled trial89No conflict of interest declaredWeight, BMI, waist and hip circumference, and appetite at 12 weeksOne gram per day produced no significant placebo-adjusted difference in any anthropometric or appetite measure.Key direct conflicting null trial
Jayawardena R et al. 2021Systematic review and meta-analysis4No external funding reportedWeight, BMI, circumference, and appetite measuresThe weight effect was about -0.04 kg, effectively zero, with only a -1.59-cm waist result and a borderline hunger signal.Synthesis confirming conflict and limitations
Rao A et al. 2021Randomized double-blind placebo-controlled trial83Gencor Pacific supplied the Slimaluma extractWeight, waist circumference, intake, and satiety biomarkersIt reported weight maintenance and some waist and intake signals versus placebo without establishing clinically meaningful weight loss.Limited positive trial of a specific branded extract
§

Receipt — 4 References

All 4 cited sources were verified for existence at the original page (as of 2026-07-19).

Arora E, Khajuria V, Tandon VR, et al. To evaluate efficacy and safety of Caralluma fimbriata in overweight and obese patients: a randomized, single blinded, placebo control trial. Perspect Clin Res. 2015;6(1):39-44. PMID: 25657901. PMCID: PMC4314845. DOI: 10.4103/2229-3485.148812.
checked
Jayawardena R, Francis TV, Abhayaratna S, Ranasinghe P. The use of Caralluma fimbriata as an appetite suppressant and weight loss supplement: a systematic review and meta-analysis of clinical trials. BMC Complement Med Ther. 2021;21:279. PMID: 34758791. PMCID: PMC8579607. DOI: 10.1186/s12906-021-03450-8.
checked
Rao A, Briskey D, Dos Reis C, Mallard AR. The effect of an orally-dosed Caralluma fimbriata extract on appetite control and body composition in overweight adults. Sci Rep. 2021;11:6791. PMID: 33762661. PMCID: PMC7991653. DOI: 10.1038/s41598-021-86108-2.
checked
Kuriyan R, Raj T, Srinivas SK, et al. Effect of Caralluma fimbriata extract on appetite, food intake and anthropometry in adult Indian men and women. Appetite. 2007;48(3):338-344. PMID: 17097761. DOI: 10.1016/j.appet.2006.09.013.
checked
Draft and rewrite: Codex (AI) · Verification: Codex blind grading and adversarial audit · Final adjudication: Claude
Reviewed and approved: Chamgap Editorial Team · Approval date: 2026-07-19 · Corrections: none

Cite this verdict

Caralluma fimbriata extract x weight loss through reduced appetite and waist circumference Evidence Grade D card
[Chamgap] Caralluma fimbriata extract x weight loss through reduced appetite and waist circumference — Evidence Grade D·35. 4 cited sources checked. Source: https://chamgap.com/en/verdicts/weight/caralluma-fimbriata-appetite-waist-weight-loss/ · CC BY 4.0

CC BY 4.0 — free to use with attribution; do not distort grades, numbers, or verdict meaning.

!

What this document does and does not do

Chamgap is an information source. It reports what research has and has not confirmed; it does not tell readers what to take or buy. That decision belongs to readers and, when needed, medical or legal professionals. This verdict reflects literature available up to the search date and may change as new research appears. Nothing here is medical advice.